Ontology type: schema:ScholarlyArticle
2007-02-15
AUTHORSSalmaan Kanji, Marc M. Perreault, Clarence Chant, David Williamson, Lisa Burry
ABSTRACTBackgroundThe purpose of this study was to characterize the usage patterns and clinical outcomes of DAA in Ontario and Quebec over a 1-year period.MethodsAll hospitals with DAA on formulary in Ontario and Quebec were invited to participate. Consecutive patients who received DAA from 1 March 2003 to 29 February 2004 were identified retrospectively. Demographic, treatment, and outcome variables were collected via chart review. Descriptive statistics on relevant variables were performed, along with logistic regression to determine relevant risk factors for survival and bleeding.ResultsThirty-seven sites participated with a total of 261 courses of DAA administered. The overall mortality rate was 45%; age (> 65 years), multiple organ system failure (> 3), and nosocomial source of sepsis were predictors of mortality, whereas early DAA administration (< 12 h) was associated with lower mortality. Serious bleeding events occurred in 10% of the patients. Only 1 case (0.4%) of fatal intracranial bleed was observed. Multiple organ system failure (≥ 4)and relative contraindications to DAA were predictors of bleeding events.InterpretationMortality and bleeding complications associated with the use of DAA were higher than that reported in randomized trials but similar to other usage database. This may be due to the higher severity of illness seen in this cohort of patients. Modifiable risks associated with mortality and bleeding, such as time to treatment, and knowledge of relative contraindications should be targets of further research and future educational efforts in order to optimize the risk-to-benefit ratio of DAA. More... »
PAGES517-523
http://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9
DOIhttp://dx.doi.org/10.1007/s00134-007-0555-9
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1027669835
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/17325837
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Anti-Infective Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Contraindications",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug Utilization",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Drug-Related Side Effects and Adverse Reactions",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hemorrhage",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infusions, Intravenous",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Logistic Models",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multivariate Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Ontario",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Product Surveillance, Postmarketing",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Protein C",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Quebec",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recombinant Proteins",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Retrospective Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Sepsis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Severity of Illness Index",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Survival Analysis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Systemic Inflammatory Response Syndrome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada",
"id": "http://www.grid.ac/institutes/grid.412687.e",
"name": [
"Department of Pharmacy, The Ottawa Hospital, Ottawa Health Research Institute, 501 Smyth Road, Room 1818, H1H 8L6, Ottawa, ON, Canada"
],
"type": "Organization"
},
"familyName": "Kanji",
"givenName": "Salmaan",
"id": "sg:person.01207613372.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01207613372.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Facult\u00e9 de Pharmacie, Pavillon Jean-Coutu, Universit\u00e9 de Montr\u00e9al, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montr\u00e9al, Qu\u00e9bec, Canada",
"id": "http://www.grid.ac/institutes/grid.14848.31",
"name": [
"Facult\u00e9 de Pharmacie, Pavillon Jean-Coutu, Universit\u00e9 de Montr\u00e9al, C.P. 6128, Succursale Centre-ville, H3C 3J7, Montr\u00e9al, Qu\u00e9bec, Canada"
],
"type": "Organization"
},
"familyName": "Perreault",
"givenName": "Marc M.",
"id": "sg:person.0772060673.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772060673.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "St. Michael\u2019s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada",
"id": "http://www.grid.ac/institutes/grid.415502.7",
"name": [
"St. Michael\u2019s Hospital, University of Toronto, 30 Bond Street, Room Q4036, M5B 1W8, Toronto, ON, Canada"
],
"type": "Organization"
},
"familyName": "Chant",
"givenName": "Clarence",
"id": "sg:person.0673055064.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673055064.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "D\u00e9partement de pharmacie, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, 5400 Gouin ouest, H4J 1C5, Montr\u00e9al, Qu\u00e9bec, Canada",
"id": "http://www.grid.ac/institutes/grid.414056.2",
"name": [
"D\u00e9partement de pharmacie, H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al, 5400 Gouin ouest, H4J 1C5, Montr\u00e9al, Qu\u00e9bec, Canada"
],
"type": "Organization"
},
"familyName": "Williamson",
"givenName": "David",
"id": "sg:person.01365714423.46",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365714423.46"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada",
"id": "http://www.grid.ac/institutes/grid.416166.2",
"name": [
"Mount Sinai Hospital, 600 University Avenue, M5G 1X5, Toronto, ON, Canada"
],
"type": "Organization"
},
"familyName": "Burry",
"givenName": "Lisa",
"id": "sg:person.01362024562.00",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362024562.00"
],
"type": "Person"
}
],
"datePublished": "2007-02-15",
"datePublishedReg": "2007-02-15",
"description": "BackgroundThe purpose of this study was to characterize the usage patterns and clinical outcomes of DAA in Ontario and Quebec over a\u00a01-year period.MethodsAll hospitals with DAA on formulary in Ontario and Quebec were invited to participate. Consecutive patients who received DAA from 1 March 2003 to 29 February 2004 were identified retrospectively. Demographic, treatment, and outcome variables were collected via chart review. Descriptive statistics on relevant variables were performed, along with logistic regression to determine relevant risk factors for survival and bleeding.ResultsThirty-seven sites participated with a\u00a0total of 261 courses of DAA administered. The overall mortality rate was 45%; age (>\u202f65 years), multiple organ system failure (>\u202f3), and nosocomial source of sepsis were predictors of mortality, whereas early DAA administration (<\u202f12\u202fh) was associated with lower mortality. Serious bleeding events occurred in 10% of the patients. Only 1 case (0.4%) of fatal intracranial bleed was observed. Multiple organ system failure (\u2265\u202f4)and relative contraindications to DAA were predictors of bleeding events.InterpretationMortality and bleeding complications associated with the use of DAA were higher than that reported in randomized trials but similar to other usage database. This may be due to the higher severity of illness seen in this cohort of patients. Modifiable risks associated with mortality and bleeding, such as time to treatment, and knowledge of relative contraindications should be targets of further research and future educational efforts in order to optimize the risk-to-benefit ratio of DAA.",
"genre": "article",
"id": "sg:pub.10.1007/s00134-007-0555-9",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1313639",
"issn": [
"0342-4642",
"1432-1238"
],
"name": "Intensive Care Medicine",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "33"
}
],
"keywords": [
"multiple organ system failure",
"organ system failure",
"relative contraindication",
"courses of DAA",
"serious bleeding events",
"fatal intracranial bleed",
"use of DAAs",
"adult severe sepsis",
"multicenter observational study",
"predictors of mortality",
"cohort of patients",
"overall mortality rate",
"relevant risk factors",
"DAA administration",
"bleeding events",
"severe sepsis",
"chart review",
"drotrecogin alfa",
"consecutive patients",
"intracranial bleed",
"clinical outcomes",
"nosocomial source",
"randomized trials",
"modifiable risk",
"risk factors",
"observational study",
"mortality rate",
"future educational efforts",
"lower mortality",
"logistic regression",
"patients",
"outcome variables",
"benefit ratio",
"mortality",
"sepsis",
"bleeding",
"contraindications",
"DAA",
"higher severity",
"descriptive statistics",
"educational efforts",
"treatment",
"risk",
"predictors",
"further research",
"complications",
"failure",
"hospital",
"alfa",
"cohort",
"illness",
"bleed",
"administration",
"trials",
"severity",
"survival",
"outcomes",
"age",
"total",
"study",
"Ontario",
"events",
"review",
"regression",
"relevant variables",
"use",
"course",
"target",
"period",
"factors",
"system failure",
"database",
"cases",
"variables",
"rate",
"Quebec",
"purpose",
"patterns",
"usage patterns",
"sites",
"knowledge",
"ratio",
"time",
"statistics",
"efforts",
"research",
"source",
"usage database",
"order"
],
"name": "Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study",
"pagination": "517-523",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1027669835"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00134-007-0555-9"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"17325837"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00134-007-0555-9",
"https://app.dimensions.ai/details/publication/pub.1027669835"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:56",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_442.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00134-007-0555-9"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00134-007-0555-9'
This table displays all metadata directly associated to this object as RDF triples.
286 TRIPLES
20 PREDICATES
138 URIs
130 LITERALS
31 BLANK NODES